--- title: "Applications – Clinical Focus and Development Areas | TEMNOGRAPHY" description: "TES HT100 is clinically evaluated as an adjunctive bedside tool in adult patients with suspected intracranial abnormalities. Current clinical focus: mild head trauma and acute neurological symptoms (TESCO programme). Clinical development: stroke pathway, thrombolytic therapy, neurological rehabilitation." source: https://www.temnography.com/applications updated: 2026-11-12 --- > This website presents medical devices and their clinical use and, in accordance with EU Regulation 2017/745 (MDR) and national law, is intended for healthcare professionals (HCP) practising in the European Union and the European Economic Area. The information provided is for professional and scientific purposes and does not replace the device Instructions for Use (IFU), clinical judgment or applicable local requirements. Product availability, regulatory status and approved intended use may vary by country. # Clinical Focus and Development Areas TES HT100 is clinically evaluated as an adjunctive bedside tool to support early assessment, risk stratification and prioritization in adult patients with suspected intracranial abnormalities. Current clinical evidence is focused on adult Emergency Department patients with mild head trauma and acute neurological symptoms, while additional applications of Temnography® technology are being explored through dedicated clinical development. The ongoing TESCO programme prospectively evaluates TES HT100 against head CT within the standard clinical pathway. TES HT100 is designed to complement, not replace, definitive anatomical imaging. ![A patient lying supine with the head inside the TES HT scanning chamber](https://www.temnography.com/images/products/hero.jpg) ## Current Clinical Focus Supported by the current prospective clinical programme (TESCO). Adult patient in the Emergency Department · →TES HT100 bedside assessment · →Risk stratification and prioritization · →CT / definitive imaging within the standard pathway 01 ### Head Trauma Supporting early assessment and triage In adult patients with mild head trauma, early identification of possible intracranial abnormalities can help healthcare professionals determine the appropriate clinical pathway and prioritize further diagnostic assessment. TES HT100 provides a rapid, non-invasive bedside assessment designed to support risk stratification and triage before definitive imaging. Head trauma represents one of the two adult patient populations currently being prospectively evaluated within the TESCO clinical programme. 02 ### Acute Neurological Symptoms Additional information before diagnostic imaging Adult patients presenting with acute neurological symptoms may require rapid evaluation to determine the need and priority for further imaging and specialist assessment. TES HT100 is designed to provide additional objective information at the bedside, supporting earlier risk stratification while maintaining CT and the established diagnostic pathway as the reference for definitive anatomical assessment. Acute neurological presentations constitute the second adult clinical cohort of the prospective TESCO programme. ### Selected Scientific Publications The clinical development of TES HT has progressed from early investigations of intracranial abnormalities to exploratory assessments in mild head trauma and the prospective TESCO programme. Peer-reviewed publications document this evolution and the growing body of clinical evidence for the TES HT platform in emergency assessment. These findings are interpreted within the populations and study designs reported in each publication. - Vaia et al. (2023) HT Temnography in the Early Diagnosis of Brain Lesions Due to Ischemic or Hemorrhagic Stroke International Journal of Advanced Research, 11(10), 191–195 [Original publication ↗ · (opens in a new tab)](https://doi.org/10.21474/IJAR01/17695) - Montemerani et al. (2024) Reliability Evaluation of Temnography for Early Detection of Intracranial Lesions in Mild Traumatic Brain Injury Patient: A Preliminary Report of a New Portable, Non-Invasive Device Open Access Emergency Medicine, 16, 313–321 [Original publication ↗ · (opens in a new tab)](https://doi.org/10.2147/OAEM.S475328) - Conte et al. (2026) Prospective Blinded Interim Evaluation of a Portable Radiofrequency Device TES HT to Support Triage in Emergency Department Patients with Mild Head Trauma or Acute Neurological Symptoms BMC Emergency Medicine, 26, 259 [Original publication ↗ · (opens in a new tab)](https://doi.org/10.1186/s12873-026-01676-8) ## Clinical Development Potential roles requiring dedicated validation. These are not established clinical indications. 03 ### Stroke Pathway Potential support for earlier patient assessment Rapid identification of patients who may present intracranial structural abnormalities could provide useful additional information during the early stroke pathway, particularly before definitive imaging is available. The potential role of Temnography® technology in supporting earlier assessment, patient prioritization and referral decisions represents an area of clinical development. 04 ### Patients under Thrombolytic Therapy Potential monitoring application through repeat bedside assessment Intracranial bleeding is an important clinical complication to consider in patients undergoing thrombolytic treatment. Because Temnography® uses non-ionizing, very low-power RF sensing and allows repeat bedside assessment when clinically appropriate, the technology may offer opportunities for investigating monitoring strategies in this clinical setting. This potential application requires dedicated clinical validation and appropriate regulatory assessment before it can be considered an established clinical use. 05 ### Neurological Rehabilitation Potential role in repeat bedside assessment Patients undergoing neurological rehabilitation may require further assessment if new or recurrent neurological symptoms occur. The non-invasive and non-ionizing characteristics of Temnography® make repeat bedside assessment an area of potential clinical interest, subject to dedicated evaluation, validation and appropriate regulatory assessment. ## Future Applications · Technology Pipeline ### A broader technology platform Temnography® is based on the measurement of tissue-specific electromagnetic behaviour using low-power broadband RF sensing. Beyond the current TES HT100 clinical programme, the same Temnography® technology platform may support the development of additional applications through dedicated devices, algorithms and clinical validation. 1. #### Temnography® technology core Low-power broadband RF sensing and computational analysis. 2. #### TES HT family The first clinically advanced product family. TES HT100 is in the prospective TESCO programme. 3. #### TES A series TES A90 and TES A100, registered medical devices in clinical development. 4. #### Future applications Dedicated devices, algorithms and clinical validation. ### TES A Series: Clinical development TES A90 and TES A100 are registered medical devices within the Temnography® development pipeline for additional clinical applications. Dedicated clinical development and validation are ongoing to define their future clinical positioning. ### Selected Scientific Publications Research supporting the development of TES A explores the potential of low-power microwave measurements and computational imaging for assessing changes in brain tissue over time. Experimental investigations of the TES platform, together with independent research in microwave brain imaging, provide a scientific basis for continued technological development and future clinical evaluation. - Cuccaro et al. (2024) Subcranial Encephalic Temnograph-Shaped Helmet for Brain Stroke Monitoring Sensors, 24, 2887 [Original publication ↗ · (opens in a new tab)](https://doi.org/10.3390/s24092887) - Rodriguez-Duarte et al. (2021) Assessing a Microwave Imaging System for Brain Stroke Monitoring via High Fidelity Numerical Modelling IEEE Journal of Electromagnetics, RF and Microwaves in Medicine and Biology, 5(3), 238–245 [Original publication ↗ · (opens in a new tab)](https://doi.org/10.1109/JERM.2020.3049071) Current evidence supports the evaluation of TES HT100 as an adjunctive bedside triage-support tool. Additional applications of Temnography® technology will require dedicated clinical development and appropriate regulatory assessment. [How TES® Works](https://www.temnography.com/technology)[Explore TES HT Products](https://www.temnography.com/products) TEMNOGRAPHY S.p.A. owns the Temnography® technology, including the related trademarks, patents and know-how. B&B S.r.l. has operated under mandate from TEMNOGRAPHY as manufacturer of the TES HT family and has been responsible for its clinical and regulatory development.